Preview

Синдром поликистозных яичников и метаболический синдром

https://doi.org/10.14341/2071-8713-4940

Полный текст:

Об авторах

I I Dedov



S A Butrova



Список литературы

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome:mechanism and implications for pathogenesis. Endocr Rev. 1997;18:774-800.

2. Dahlgren E., Janson P.Q., Johansson S. Women with polycystic ovary syndrome wedge resected in 1956 to 1965 a long term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992;57:505-13.

3. Legro R.S., Kunselman A.R., Dodson W.C., Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome:a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-9.

4. Ehrmann D., Barnes R., Rosenfield R., Cavaghan M. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-3.

5. Talbott E., Guzick D., Clerici A., Berga S., Detre K., Weimer K. et al. Сoronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Ttiromb Vasc Biol. 1995;15:821-6.

6. Cibula D., Citcova R., Fanta M., Poledne R., Zivny J., Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with hystiry of the polycystic ovary syndrome. Hum Reprod. 2000;15:785-9.

7. Peppard H.R., Marfori J., luorno M.J.,Nestler J.R. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care. 2001;24:1050-2.

8. Guzick D.S. Polycystic Ovary Syndrome. 2004;103:181-93.

9. Micola M., Hiilesmaa V., Halttunen M., Shonen L., Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001;16:226-9.

10. Morin-Papunen L.C., Vauhkonen I., Koivunen R. M. et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome:a randomized study. J Clin Endocrinol Metab. 2000;85:3161-8.

11. Legro R.S., Kunselman A.R., Dunaif A. Prevalence and predictors of dislipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607-13.

12. Holte J., Bergh Т., Gennarelli G., Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf). 1994;41:473-81.

13. Takanashi M., Funahashi Т., Shimomura I. et al. Plasma leptin levels and body fat distribution. Horm Metab Res. 1996;28:751-2.

14. Unger R.H. Lipotoxic Diseases. Annu Rev Med. 2002;53:319-36.

15. Porter M.H., Cuthins A., Fine J.B. et al. Effects of TNF-a on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J Clin Med. 2002;139:140-6.

16. Pajvani UB, Scherer PE. Adiponectin:systemic contributor to insulin sensitivity. Curr Diab Rep. 2003;3:207-13.

17. Spranger J., Kroke A., Mhlig M. et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226-8.

18. Okamoto Y, Arita Y, Nishida M. et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res. 2000;32:47-50.

19. Orio F., Palomba S.,Cascella T. et al. Adiponectin levels in Women with Polycystic Ovary Syndrome. J Clin Endocrin. 2003;88:2619-26.

20. Wld R.A., Painter P. C, Coulson P. B. et al. Lipoprotein lipid concentrations and cardiovascular risr in women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 1982;51:946-51.

21. Conway G.S., Agrawal R., Betteridge D.J., Jacobs H.S. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1002;37:119-25.

22. Talbott E., Guzic D., Clerici A. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromv Vase Biol. 1995;15:821-6.

23. Pirwany I.R., Fleming R., Greer I.A. et al. Lipids and lipoprotein subtractions in women with PCOS:relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf). 2001;54:447-53.

24. Dahlgren E., Johansson S., Lindstedt G. Women with polycystic ovary syndrome wedge resected in 1956 to 1965:a long term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992;57:595-13.

25. Cibula D., Cifkova R., Fanta M. et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod. 2000;15:785-9.

26. Christian R.C., Dumesic D.A., Behrenbeck T. et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2003;88:2562-8.

27. Dahlgren E., Janson P. O., Johansson S. et al. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynaecol Scand. 1992;71:599-604.

28. Apridonidze Т., Essah P.A., luorno M.J. et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol. 2004;10:1210/jc 2004-1045.

29. Legro R. S. Polycystic ovary syndrome and cardiovascular disease:a premature association? Endocr Rev. 2003;24:302-12.

30. Pasquali R., Casimirri F., Vicennati V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod. 1997;12:82-7.

31. Kiddy D.S., Hamilton-Firley D., Bush A. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (oxf) 1992;36:105-11.

32. Huber-Bucholz M. M., Carey D., Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome. J Clin Endocrinol Metab. 1999;84:1470-4.

33. Andersen P., Seljeflot I., Abdelnoor M. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women polycystic ovary syndrome. Metabolism. 1995;44:611-6.

34. Charles A., Vague P., Morange P. et al. Effect of weight change and metformin on fibrinolysis and the von Wllebrand factor in obese nondiabetic subjects. The BINGPRI Study. Diabetes Care. 1988;11:1967-72.

35. Diamanti-Kandarakis E., Kouli C., Tsianateli Т., Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998;138:269-74.

36. Morin-Papunen L. C, Vauhkonen I., Koivunen R. M. et al. Endocrine and metabolic effects of metformin vs.ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome:a randomized study. J Clin Endocrinol Metabol. 2000;85:3161-8

37. Moghetti P., Castello R., Negri С et al. Metformin effectson clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome;a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metabol. 2000;85:139-46.

38. Карпова Е.А., Пищулин АА.ю Андреева Е.Н. Применение бигуанидов при синдроме поликистозных яичников. Ожирение и метаболизм. 2004;1:30-33.

39. Nestler J. E., Jakubowcz D. L. et al. Effects of metformin on spontaneous and clomiphene induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876-80.

40. Harborne L., Fleming R., Lyall H. et al. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361:1894-901.

41. Moren-Popunen L., Rautio K., Ruokonen A. et al. Metformin reduces Serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol. 2003;88:4649-54.

42. Okuno A., Tamemoto H. et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Diabetes. 1998;101:1354-61.

43. Дедов И.И., Пищулин А.А., Яровая И.С., Акмаев Р.И. Опыт применения пиоглитазона (Актоса) в лечении синдрома поликистозных яичников. Пробл эндокр. 2005;1:15-19.

44. Romualdi D., Guido M. et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod. 2003;18:1210-8.


Для цитирования:


Dedov I.I., Butrova S.A. Синдром поликистозных яичников и метаболический синдром. Ожирение и метаболизм. 2006;3(1):30-40. https://doi.org/10.14341/2071-8713-4940

For citation:


., . Sindrom polikistoznykh yaichnikov i metabolicheskiy sindrom. Obesity and metabolism. 2006;3(1):30-40. (In Russ.) https://doi.org/10.14341/2071-8713-4940

Просмотров: 16


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)